MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Wednesday

Key Points

• MoonLake Immunotherapeutics is set to release its Q1 2025 earnings report on August 6th, with analysts predicting a loss of ($0.73) per share.
• The company's previous earnings report in May showed a loss of ($0.63) per share, which exceeded analysts' estimates of ($0.76) per share.
• Several research firms have assigned an "outperform" rating to MoonLake Immunotherapeutics, with price targets ranging from $61.00 to $80.00.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect MoonLake Immunotherapeutics to post earnings of ($0.73) per share for the quarter.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.13. During the same quarter last year, the business posted ($0.22) EPS. On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MoonLake Immunotherapeutics Trading Up 4.9%

Shares of MLTX traded up $2.48 during mid-day trading on Friday, reaching $52.92. The company had a trading volume of 957,582 shares, compared to its average volume of 509,369. The stock has a market cap of $3.39 billion, a price-to-earnings ratio of -23.01 and a beta of 1.27. The company has a current ratio of 21.11, a quick ratio of 21.11 and a debt-to-equity ratio of 0.18. The firm has a fifty day simple moving average of $47.46 and a 200-day simple moving average of $42.85. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $58.26.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Redburn Atlantic upgraded shares of MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Royal Bank Of Canada reissued an "outperform" rating and issued a $67.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 3rd. Needham & Company LLC restated a "buy" rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Wedbush reissued an "outperform" rating and issued a $80.00 price objective (up from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Finally, Rothschild & Co Redburn initiated coverage on MoonLake Immunotherapeutics in a research report on Monday, July 28th. They issued a "neutral" rating and a $65.00 target price for the company. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $73.14.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MoonLake Immunotherapeutics stock. Millennium Management LLC increased its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 3,343.2% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 344,320 shares of the company's stock after purchasing an additional 334,320 shares during the period. Millennium Management LLC owned 0.54% of MoonLake Immunotherapeutics worth $13,453,000 at the end of the most recent reporting period. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.